Physician profile

Wen L Wang

Infectious Disease · Flushing, NY

NPI 1568421998

$862.22

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$175.81

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Samsung Hme America, INC. $183.80 2019
Viiv Healthcare Company $155.34 2020-2021
Abbott Laboratories $135.25 2023 Freestyle Libre 3
Melinta Therapeutics, LLC $122.18 2019-2020
Janssen Scientific Affairs, LLC $69.39 2022-2023
Gilead Sciences, INC. $66.54 2020-2021
Daiichi Sankyo INC. $47.51 2020
Abbvie INC. $39.70 2022-2023 Dalvance
Pfizer INC. $24.88 2021
Allergan, INC. $17.63 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Wen L Wang

$862.22

in general payments reported 2019-2025

Years
2019-2023
Top company
Samsung Hme America, INC.

https://glasscript.com/doctor/71004/wen-l-wang

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.